 | Up a level |
2022
Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M. J., Arcila, M. E., Arrieta, O., Planchard, D., de Marinis, F., Dingemans, A. M., Dziadziuszko, R., Faivre-Finn, C., Feldman, J., Felip, E., Curigliano, G., Herbst, R., Janne, P. A., John, T., Mitsudomi, T., Mok, T., Normanno, N., Paz-Ares, L., Ramalingam, S., Sequist, L., Vansteenkiste, J., Wistuba, I. I., Wolf, J., Wu, Y. L., Yang, S. R., Yang, J. C. H., Yatabe, Y., Pentheroudakis, G. and Peters, S. (2022). ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol., 33 (5). S. 466 - 488. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2020
Wolf, J., Planchard, D., Heist, R. S., Solomon, B., Sebastian, M., Santoro, A., Reguart, N., Stammberger, U., Manganelli, L., Wu, H., Mais, A. and Dooms, C. (2020). Phase Ib study of LXH254+LTT462 in patients with KRAS- or BRAF-mutant NSCLC. Ann. Oncol., 31. S. S881 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2017
Eberhardt, W. E. E., Rebmann, V., Rizvi, N., Antonia, S. J., Planchard, D., Cappuzzo, F., Mazieres, J., Zalcman, G., Lena, H., Wolf, J., Horn, L., Stinchcombe, T., Dy, G., Blackwood-Chirchir, A., Jin, C., Geese, W. J. and Ramalingam, S. S. (2017). First signal-finding study of soluble HLA-G and -E (sHLA-G/E) as potential prognostic markers of clinical outcome in advanced, refractory squamous-cell NSCLC (SCC) treated with nivolumab (NIVO): checkMate 063. Oncol. Res. Treat., 40. S. 218 - 220. BASEL: KARGER. ISSN 2296-5262
2014
Ramalingam, S. S., Mazieres, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Baudelet, C., Lestini, B. J. and Rizvi, N. A. (2014). Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys., 90 (5). S. 1266 - 1268. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X